The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Sernyak, M. J.
* Articles by Rosenheck, R.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Sernyak, M. J.
* Articles by Rosenheck, R.
Related Collections
* Schizophrenia Spectrum Disorders
* Other Neuroleptics
Am J Psychiatry 159:561-566, April 2002
© 2002 American Psychiatric Association

Article

Association of Diabetes Mellitus With Use of Atypical Neuroleptics in the Treatment of Schizophrenia

Michael J. Sernyak, M.D., Douglas L. Leslie, Ph.D., Renato D. Alarcon, M.D., Miklos F. Losonczy, M.D., Ph.D., and Robert Rosenheck, M.D.

OBJECTIVE: The development of both type I and type II diabetes after initiation of some atypical neuroleptics has been reported, primarily in studies involving small series of patients. This study used administrative data from a large national sample of patients with a diagnosis of schizophrenia to compare the prevalence of diabetes mellitus in patients receiving prescriptions for atypical and typical neuroleptics. METHOD: All outpatients with schizophrenia treated with typical and atypical neuroleptics over 4 months in 1999 in the Veterans Health Administration of the Department of Veterans Affairs (VA) were included in this study. Patients treated with atypical neuroleptics were those who received prescriptions for clozapine, olanzapine, risperidone, or quetiapine. Patients with a diagnosis of diabetes were also identified by using ICD-9 codes in VA administrative databases. The prevalence of diabetes mellitus across age groups and among patients receiving prescriptions for different atypical neuroleptics was examined with multiple logistic regression. RESULTS: A total of 38,632 patients were included in the study: 15,984 (41.4%) received typical neuroleptics and 22,648 (58.6%) received any atypical neuroleptic (1,207 [5.3%] received clozapine; 10,970 [48.4%], olanzapine; 955 [4.2%], quetiapine; and 9,903 [43.7%], risperidone; 387 patients received prescriptions for more than one atypical neuroleptic). When the effects of age were controlled, patients who received atypical neuroleptics were 9% more likely to have diabetes than those who received typical neuroleptics, and the prevalence of diabetes was significantly increased for patients who received clozapine, olanzapine, and quetiapine, but not risperidone. However, for patients less than 40 years old, all of the atypical neuroleptics were associated with a significantly increased prevalence of diabetes. CONCLUSIONS: In this large group of patients with schizophrenia, receipt of a prescription for atypical neuroleptics was significantly associated with diabetes mellitus.




This article has been cited by other articles:


Home page
 Psychiatr. Serv.Home page
M. J. Sernyak and R. A. Rosenheck
Antipsychotic Use in the Treatment of Outpatients With Schizophrenia in the VA From Fiscal Years 1999 to 2006
Psychiatr Serv, May 1, 2008; 59(5): 567 - 569.
[Abstract] [Full Text] [PDF]

Home page
 PsychosomaticsHome page
D. Dickinson, J. M. Gold, F. B. Dickerson, D. Medoff, and L. B. Dixon
Evidence of Exacerbated Cognitive Deficits in Schizophrenia Patients With Comorbid Diabetes
Psychosomatics, April 1, 2008; 49(2): 123 - 131.
[Abstract] [Full Text] [PDF]

Home page
 Schizophr BullHome page
R.A. Rosenheck, D.L. Leslie, S. Busch, E. S. Rofman, and M. Sernyak
Rethinking Antipsychotic Formulary Policy
Schizophr Bull, March 1, 2008; 34(2): 375 - 380.
[Abstract] [Full Text] [PDF]

Home page
 cfpHome page
D. Behroozi, G. Mazowita, and M. D. Davis
Collaboration in caring for psychiatric inpatients: Family physicians team up with psychiatrists and psychiatric nurses
Can Fam Physician, January 1, 2008; 54(1): 57 - 57.
[Abstract] [Full Text] [PDF]

Home page
 Schizophr BullHome page
O. Sentissi, J. Epelbaum, J.-P. Olie, and M.-F. Poirier
Leptin and Ghrelin Levels in Patients With Schizophrenia During Different Antipsychotics Treatment: A Review
Schizophr Bull, December 28, 2007; (2007) sbm141v1.
[Abstract] [Full Text] [PDF]

Home page
 Schizophr BullHome page
M. Olfson, S. C. Marcus, and H. Ascher-Svanum
Treatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone
Schizophr Bull, November 1, 2007; 33(6): 1379 - 1387.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
J. Hippisley-Cox, C. Parker, C. Coupland, and Y. Vinogradova
Inequalities in the primary care of patients with coronary heart disease and serious mental health problems: a cross-sectional study
Heart, October 1, 2007; 93(10): 1256 - 1262.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
L. L Citrome, R. I. Holt, W. M Zachry, J. D Clewell, P. A Orth, J. L Karagianis, and V. P. Hoffmann
Risk of Treatment-Emergent Diabetes Mellitus in Patients Receiving Antipsychotics
Ann. Pharmacother., October 1, 2007; 41(10): 1593 - 1603.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
R. L Dufresne
Weighing In: Emergent Diabetes Mellitus and Second-Generation Antipsychotics
Ann. Pharmacother., October 1, 2007; 41(10): 1725 - 1727.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
A.H. Barnett, P. Mackin, I. Chaudhry, A. Farooqi, R. Gadsby, A. Heald, J. Hill, H. Millar, R. Peveler, A. Rees, et al.
Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia
J Psychopharmacol, June 1, 2007; 21(4): 357 - 373.
[Abstract] [PDF]

Home page
 Am J Health Syst PharmHome page
J. M. Noel
ASHP Therapeutic Position Statement on the Use of Second-Generation Antipsychotic Medications in the Treatment of Adults with Psychotic Disorders
Am. J. Health Syst. Pharm., April 15, 2007; 64(8): 863 - 876.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
B. Chavez and R. A Poveda
Efficacy with High-Dose Aripiprazole After Olanzapine-Related Metabolic Disturbances
Ann. Pharmacother., December 1, 2006; 40(12): 2265 - 2268.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
S. Burton
Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
J Psychopharmacol, November 1, 2006; 20(6 Suppl): 6 - 19.
[Abstract] [PDF]

Home page
 J PsychopharmacolHome page
M. S Turner and D. W Stewart
Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
J Psychopharmacol, November 1, 2006; 20(6 Suppl): 20 - 37.
[Abstract] [PDF]

Home page
 J PsychopharmacolHome page
P. Chue
The relationship between patient satisfaction and treatment outcomes in schizophrenia.
J Psychopharmacol, November 1, 2006; 20(6 Suppl): 38 - 56.
[Abstract] [PDF]

Home page
 Am J EpidemiolHome page
B. L. Lambert, F. E. Cunningham, D. R. Miller, G. W. Dalack, and K. Hur
Diabetes Risk Associated with Use of Olanzapine, Quetiapine, and Risperidone in Veterans Health Administration Patients with Schizophrenia
Am. J. Epidemiol., October 1, 2006; 164(7): 672 - 681.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. Serv.Home page
S. L. Krein, C. R. Bingham, J. F. McCarthy, A. Mitchinson, J. Payes, and M. Valenstein
Diabetes Treatment Among VA Patients With Comorbid Serious Mental Illness
Psychiatr Serv, July 1, 2006; 57(7): 1016 - 1021.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
Z. T. Bloomgarden
Atypical Antipsychotic Agents, Retinopathy, Nephropathy, and Cardiovascular Disease.
Diabetes Care, June 1, 2006; 29(6): 1439 - 1446.
[Full Text] [PDF]

Home page
 Psychiatr. Serv.Home page
E. M. Weissman, D. M. Moot, and S. M. Essock
What Do People With Schizophrenia Think About Weight Management?
Psychiatr Serv, May 1, 2006; 57(5): 724 - 725.
[Full Text] [PDF]

Home page
 Research on Social Work PracticeHome page
J. R. Bola
Psychosocial Acute Treatment in Early-Episode Schizophrenia Disorders
Research on Social Work Practice, May 1, 2006; 16(3): 263 - 275.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
D. Cohen, R. P. Stolk, D. E. Grobbee, and C. C. Gispen-de Wied
Hyperglycemia and Diabetes in Patients With Schizophrenia or Schizoaffective Disorders
Diabetes Care, April 1, 2006; 29(4): 786 - 791.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
F. Gianfrancesco, J. Pesa, R.-H. Wang, and H. Nasrallah
Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: Sensitivity to study design
Am. J. Health Syst. Pharm., March 1, 2006; 63(5): 431 - 441.
[Abstract] [Full Text] [PDF]

Home page
 AJGPHome page
J. L. Micca, V. P. Hoffmann, I. Lipkovich, J. Ahl, R. W. Baker, and T. A. Hardy
Retrospective Analysis of Diabetes Risk in Elderly Patients With Dementia in Olanzapine Clinical Trials
Am J Geriatr Psychiatry, January 1, 2006; 14(1): 62 - 70.
[Abstract] [Full Text] [PDF]

Home page
 Clin. DiabetesHome page
M. D. Llorente and V. Urrutia
Diabetes, Psychiatric Disorders, and the Metabolic Effects of Antipsychotic Medications
Clin. Diabetes, January 1, 2006; 24(1): 18 - 24.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
H. Hosojima, T. Togo, T. Odawara, K. Hasegawa, S. Miura, Y. Kato, A. Kanai, A. Kase, H. Uchikado, and Y. Hirayasu
Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia
J Psychopharmacol, January 1, 2006; 20(1): 75 - 79.
[Abstract] [PDF]

Home page
 J PsychopharmacolHome page
S. Tighe and T. Dinan
An overview of the central control of weight regulation and the effect of antipsychotic medication
J Psychopharmacol, November 1, 2005; 19(6_suppl): 36 - 46.
[Abstract] [PDF]

Home page
 J PsychopharmacolHome page
R. I. G. Holt, C. Bushe, and L. Citrome
Diabetes and schizophrenia 2005: are we any closer to understanding the link?
J Psychopharmacol, November 1, 2005; 19(6_suppl): 56 - 65.
[Abstract] [PDF]

Home page
 NEJMHome page
R. Freedman
The Choice of Antipsychotic Drugs for Schizophrenia
N. Engl. J. Med., September 22, 2005; 353(12): 1286 - 1288.
[Full Text] [PDF]

Home page
 J PsychopharmacolHome page
V. J. Fedorowicz and E. Fombonne
Metabolic side effects of atypical antipsychotics in children: a literature review
J Psychopharmacol, September 1, 2005; 19(5): 533 - 550.
[Abstract] [PDF]

Home page
 AJGPHome page
W. G. Deberdt, M. W. Dysken, S. A. Rappaport, P. D. Feldman, C. A. Young, D. P. Hay, D. L. Lehman, M. Dossenbach, E. K. Degenhardt, and A. Breier
Comparison of Olanzapine and Risperidone in the Treatment of Psychosis and Associated Behavioral Disturbances in Patients With Dementia
Am J Geriatr Psychiatry, August 1, 2005; 13(8): 722 - 730.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. Serv.Home page
C. R. Richardson, G. Faulkner, J. McDevitt, G. S. Skrinar, D. S. Hutchinson, and J. D. Piette
Integrating Physical Activity Into Mental Health Services for Persons With Serious Mental Illness
Psychiatr Serv, March 1, 2005; 56(3): 324 - 331.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
D. Taylor, C. Young, R. Mohamed, C. Paton, and R. Walwyn
Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs
J Psychopharmacol, March 1, 2005; 19(2): 182 - 186.
[Abstract] [PDF]

Home page
 Psychiatr. Serv.Home page
R. A. Rosenheck
Open Forum: Effectiveness Versus Efficacy of Second-Generation Antipsychotics: Haloperidol Without Anticholinergics as a Comparator
Psychiatr Serv, January 1, 2005; 56(1): 85 - 92.
[Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
L. E. Davis, M. W. Becher, W. Tlomak, B. E. Benson, R. R. Lee, and E. C. Fisher
Persistent Choreoathetosis in a Fatal Olanzapine Overdose: Drug Kinetics, Neuroimaging, and Neuropathology
Am J Psychiatry, January 1, 2005; 162(1): 28 - 33.
[Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
D. C. Henderson, E. Cagliero, P. M. Copeland, C. P. Borba, E. Evins, D. Hayden, M. T. Weber, E. J. Anderson, D. B. Allison, T. B. Daley, et al.
Glucose Metabolism in Patients With Schizophrenia Treated With Atypical Antipsychotic Agents: A Frequently Sampled Intravenous Glucose Tolerance Test and Minimal Model Analysis
Arch Gen Psychiatry, January 1, 2005; 62(1): 19 - 28.
[Abstract] [Full Text] [PDF]

Home page
 FocusHome page
S. B. Schur, L. Sikich, R. L. Findling, R. P. Malone, M. L. Crismon, A. Derivan, J. C. MacIntyre II, E. Pappadopulos, L. Greenhill, N. Schooler, et al.
Treatment Recommendations for the Use of Antipsychotics for Aggressive Youth (TRAAY), Part I: A Review
Focus, October 1, 2004; 2(4): 596 - 607.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. Serv.Home page
R. A. Rosenheck
Back to the Future: Funding, Integrating, and Improving Mental Health Services
Psychiatr Serv, October 1, 2004; 55(10): 1141 - 1142.
[Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
G. M. Simpson, I. D. Glick, P. J. Weiden, S. J. Romano, and C. O. Siu
Randomized, Controlled, Double-Blind Multicenter Comparison of the Efficacy and Tolerability of Ziprasidone and Olanzapine in Acutely Ill Inpatients With Schizophrenia or Schizoaffective Disorder
Am J Psychiatry, October 1, 2004; 161(10): 1837 - 1847.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. Serv.Home page
L. Citrome, A. Jaffe, J. Levine, B. Allingham, and J. Robinson
Relationship Between Antipsychotic Medication Treatment and New Cases of Diabetes Among Psychiatric Inpatients
Psychiatr Serv, September 1, 2004; 55(9): 1006 - 1013.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
D. L. Leslie and R. A. Rosenheck
Incidence of Newly Diagnosed Diabetes Attributable to Atypical Antipsychotic Medications
Am J Psychiatry, September 1, 2004; 161(9): 1709 - 1711.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. Serv.Home page
L. B. Dixon, J. A. Kreyenbuhl, F. B. Dickerson, T. W. Donner, C. H. Brown, K. Wolheiter, L. Postrado, R. W. Goldberg, L. Fang, C. Marano, et al.
A Comparison of Type 2 Diabetes Outcomes Among Persons With and Without Severe Mental Illnesses
Psychiatr Serv, August 1, 2004; 55(8): 892 - 900.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
M. V. Seeman
Gender Differences in the Prescribing of Antipsychotic Drugs
Am J Psychiatry, August 1, 2004; 161(8): 1324 - 1333.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
S. R. Marder, S. M. Essock, A. L. Miller, R. W. Buchanan, D. E. Casey, J. M. Davis, J. M. Kane, J. A. Lieberman, N. R. Schooler, N. Covell, et al.
Physical Health Monitoring of Patients With Schizophrenia
Am J Psychiatry, August 1, 2004; 161(8): 1334 - 1349.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. Gentile
Clinical Utilization of Atypical Antipsychotics in Pregnancy and Lactation
Ann. Pharmacother., July 1, 2004; 38(7): 1265 - 1271.
[Abstract] [Full Text] [PDF]

Home page
 J Am Psychiatr Nurses AssocHome page
B. Vreeland and E. Kim
Managing the Clinical Consequences of Psychiatric Illness and Antipsychotic Treatment: A Discussion of Obesity, Diabetes, and Hyperprolactinemia
Journal of the American Psychiatric Nurses Association, June 1, 2004; 10(3_suppl): S17 - S24.
[Abstract] [PDF]

Home page
 Diabetes Spectr.Home page
J. K. Kaholokula, T. N. Schirmer, and D. Elting
Identifying and Prioritizing Diabetes Care Issues Among Mental Health Professionals of a Multi-Ethnic, State Psychiatric Hospital
Diabetes Spectr, April 1, 2004; 17(2): 123 - 128.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
C. Bushe and R. Holt
Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia
The British Journal of Psychiatry, April 1, 2004; 184(47): s67 - s71.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
J. H. Thakore
Metabolic disturbance in first-episode schizophrenia
The British Journal of Psychiatry, April 1, 2004; 184(47): s76 - s79.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
P. M. Haddad
Antipsychotics and diabetes: review of non-prospective data
The British Journal of Psychiatry, April 1, 2004; 184(47): s80 - s86.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
C. Bushe and B. Leonard
Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data
The British Journal of Psychiatry, April 1, 2004; 184(47): s87 - s93.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
P. Cavazzoni, N. Mukhopadhyay, C. Carlson, A. Breier, and J. Buse
Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications
The British Journal of Psychiatry, April 1, 2004; 184(47): s94 - s101.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
M. Peet
Diet, diabetes and schizophrenia: review and hypothesis
The British Journal of Psychiatry, April 1, 2004; 184(47): s102 - s105.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
S. Gough and R. Peveler
Diabetes and its prevention: pragmatic solutions for people with schizophrenia
The British Journal of Psychiatry, April 1, 2004; 184(47): s106 - s111.
[Abstract] [Full Text] [PDF]